Tag: I-Mab

Clinical-stage biopharmaceutical company NovaBridge Biosciences, formerly known as I-Mab, has released compelling updated Phase 1 data for its bispecific antibody ...

Despite facing recent downward pressure on its share price, I-Mab continues to receive a largely favorable assessment from market analysts. ...

The Chinese biotech firm I-Mab (NASDAQ: IMAB) is making waves with its experimental cancer therapy, but investors should brace for ...